| Revision as of 09:18, 19 February 2008 editRcej (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers15,369 editsm two categories← Previous edit | Revision as of 12:23, 6 April 2008 edit undoSmackBot (talk | contribs)3,734,324 editsm Add references section and/or general fixes.Next edit → | ||
| Line 19: | Line 19: | ||
| ==References== | ==References== | ||
| <references /> | |||
| ⚫ | {{Metabolic pathology}} | ||
| ] | ] | ||
| Line 25: | Line 28: | ||
| {{genetic-disorder-stub}} | {{genetic-disorder-stub}} | ||
| ⚫ | {{Metabolic pathology}} | ||
| ] | ] | ||
Revision as of 12:23, 6 April 2008
Medical condition| Phosphofructokinase deficiency | |
|---|---|
| Specialty | Endocrinology  |
Phosphofructokinase deficiency, also known as Glycogen storage disease type VII or Tarui's disease, is metabolic disorder with autosomal recessive inheritance, in which deficiency of the M subunit of the phosphofructokinase enzyme impairs the ability of cells such as erythrocytes and rhabdomyocytes to use carbohydrates (such as glucose) for energy. It may affects humans as well as other mammals (especially dogs). In humans it is the least common type of glycogen storage disease.
Presentation
The disease presents with exercise-induced muscle cramps and weakness (sometimes rhabdomyolysis), as well as with haemolytic anaemia causing dark urine a few hours later.
References
 | This genetic disorder article is a stub. You can help Misplaced Pages by expanding it. |